A Phase 3 Randomized Controlled Trial to Evaluate Efficacy and Safety of New-Formulation Zenon (Rosuvastatin/Ezetimibe Fixed-Dose Combination) in Primary Hypercholesterolemia Inadequately Controlled by Statins
Objective: In primary hypercholesterolemia many people treated with statins do not reach their plasma LDL-C goals and are at increased risk of cardiovascular disease (CVD). This study aimed to evaluate efficacy and safety of a new fixed-dose combination (FDC) formulation of rosuvastatin/ezetimibe (R...
Main Authors: | Alberico L. Catapano MD, PhD, Michal Vrablik MD, PhD, Yuri Karpov MD, Baptiste Berthou Lic, Megan Loy BAppSc, Marie Baccara-Dinet MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-11-01
|
Series: | Journal of Cardiovascular Pharmacology and Therapeutics |
Online Access: | https://doi.org/10.1177/10742484221138284 |
Similar Items
-
Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?Novel Teaching Points
by: Shyann Hang, BSc, et al.
Published: (2022-04-01) -
Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights
by: Chilbert MR, et al.
Published: (2022-07-01) -
The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial
by: Karolina Obońska, et al.
Published: (2017-07-01) -
Fixeddose combination of rosuvastatin + ezetimibe: ease of use, safety and efficacy
by: I. A. Alekseeva, et al.
Published: (2019-10-01) -
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9[S]
by: Brandon Ason, et al.
Published: (2011-04-01)